Efficacy of antipsychotics in delusional infestation

Tang, Paul K., Lepping, Peter, Lepping, Sophie G., Noorthoorn, Eric O., Squire, Bertie ORCID: https://orcid.org/0000-0001-7173-9038, Mohandas, Padma and Bewley, Anthony (2024) 'Efficacy of antipsychotics in delusional infestation'. Journal of the European Academy of Dermatology and Venereology. (In Press)

	Text FINAL, Antipsychotics in DI study JEADV.pdf - Accepted Version Restricted to Repository staff only until 10 May 2025. Download (309kB)
	Text Table 1.pdf - Supplemental Material Restricted to Repository staff only until 10 May 2025. Download (137kB)
	Text Table 2.pdf - Supplemental Material Restricted to Repository staff only until 10 May 2025. Download (155kB)
	Text Figure 1.pdf - Supplemental Material Restricted to Repository staff only until 10 May 2025. Download (136kB)
	Text Figure 2.pdf - Supplemental Material Restricted to Repository staff only until 10 May 2025. Download (117kB)

Abstract

Background
Data remain scarce for the first‐line antipsychotic choice in treating delusional infestation (DI).
Objectives
We evaluated the treatment responses associated with different antipsychotics in DI patients.
Methods
We undertook a multicentre, retrospective observational study using anonymised electronic patient records from two hospitals in the United Kingdom from 1 January 2011 to 1 January 2023. Eligible participants were adults (≥18 years) diagnosed with DI treated with an antipsychotic, and had both an assigned baseline and follow‐up Clinical Global Impression Scale (CGI‐S) score. The CGI‐S is a validated psychiatric research tool. Participants were excluded if they had known limited or non‐adherence to an antipsychotic, or if no CGI‐S scores were present at follow‐up. First clinic visits before the initiation of an antipsychotic were assigned as the baseline CGI‐S score. The last available CGI‐S score before the patient either changed antipsychotic or left the clinic for any reason was used to assign follow‐up CGI‐S scores. The primary outcome was the response to each individual antipsychotic treatment, measured by the difference in the baseline and last available follow‐up CGI‐S scores. Differences in CGI‐S changes between antipsychotic episodes were tested by analysis of variance (ANOVA).
Results
In total, 414 patient records were analysed, and data were extracted. The mean age was 61.8 years (SD 14.1). One hundred seventy (41%) of 414 patients were men and 244 (59%) were women. In total, 156 (38%) of 414 patients were eligible, yielding a total of 315 antipsychotic prescribing episodes. The ANOVA, ranking in order of treatment response, showed that the highest mean score (expressing highest treatment response) was observed in amisulpride (31 [67%] of 46) and risperidone (95 [57%] of 167), followed by some distance by quetiapine (9 [36%] of 25), aripiprazole (13 [28%] of 46) and olanzapine (7 [25%] of 28).
Conclusions
Amisulpride and risperidone were associated with a higher treatment response than quetiapine, aripiprazole and olanzapine. Amisulpride and risperidone should therefore be considered the first‐line treatment options in DI patients.

Item Type:	Article
Subjects:	QV Pharmacology > Central Nervous System Agents. Local Anesthetics > QV 77 Psychopharmacology QV Pharmacology > Central Nervous System Agents. Local Anesthetics > QV 77.2 Psychotropic drugs WR Dermatology > WR 20 Research (General)
Faculty: Department:	Clinical Sciences & International Health > Clinical Sciences Department
Digital Object Identifer (DOI):	https://doi.org/10.1111/jdv.20081
SWORD Depositor:	JISC Pubrouter
Depositing User:	JISC Pubrouter
Date Deposited:	16 Jul 2024 12:48
Last Modified:	11 Dec 2024 15:15
URI:	https://archive.lstmed.ac.uk/id/eprint/24590

Statistics

View details

Actions (login required)

Edit Item